Kai Zu, MD
Hematology & Oncology · la Mesa, CANPI 1164583639
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $35,510 of the $43,852 with a category attached, or 81.0%. 60 manufacturers reported payments, led by AstraZeneca at 25.6% of the total. Reporting peaked in 2020 at $13,559 and has fallen 82.7% since, to $2,344 in 2025.
Across 293 payments — averaging $149.66 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$11K
- Acceleron Pharma, Inc.$10K
- Incyte Corporation$4K
- Bristol Myers Squibb$4K
- Dova Pharmaceuticals$3K
- Takeda Pharmaceuticals U.S.A., Inc.$2K
- plus $10K from 54 others
Across 77 payments — averaging $4948.39 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- GSK$180K
- Astrazeneca UK Limited$64K
- Eli Lilly$51K
- E.r. Squibb & Sons, L.L.C.$38K
- AstraZeneca$31K
- Mirati Therapeutics, Inc.$12K
- plus $5K from 1 others
What the payments were for
- Consulting fees$35,51081%
- Speaking & faculty fees$2,1255%
- Travel & lodging$2201%
- Food & beverage$5,82013%
- Education$1770%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$43,852 in reported general payments places this provider in the 85th percentile of 1,363 hematology & oncology providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| BrukinsaZanubrutinib | 49 | $597,340 |
| Lenalidomide | 37 | $542,908 |
| ReblozylLuspatercept-Aamt | 34 | $479,516 |
| KisqaliRibociclib Succinate | 26 | $445,566 |
| CalquenceAcalabrutinib Maleate | 29 | $444,115 |
| PomalystPomalidomide | 22 | $440,739 |
| IbrancePalbociclib | 27 | $413,631 |
| TagrissoOsimertinib Mesylate | 24 | $407,367 |
| RevlimidLenalidomide | 19 | $358,894 |
| XtandiEnzalutamide | 22 | $304,426 |
| RetevmoSelpercatinib | 13 | $289,623 |
| TasignaNilotinib Hcl | 15 | $257,181 |
| AlunbrigBrigatinib | 12 | $230,609 |
| ImbruvicaIbrutinib | 13 | $213,145 |
| VerzenioAbemaciclib | 12 | $172,834 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| E.r. Squibb & Sons, L.L.C.Reblozyl, Pomalyst | $364 | $920,25556 claims |
| AstraZenecaCalquence, Tagrisso | $11,243 | $851,48253 claims |
| NovartisKisqali, Tasigna | $482 | $702,74741 claims |
| Beigene USA, Inc.Brukinsa | $1,441 | $597,34049 claims |
| PfizerIbrance, Retacrit | $481 | $417,48740 claims |
| Bristol Myers SquibbRevlimid | $3,695 | $358,89419 claims |
| Astellas Pharma US IncXtandi | $689 | $304,42622 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Alunbrig | $1,674 | $230,60912 claims |
| Pharmacyclics LLC, An Abbvie CompanyImbruvica | $280 | $213,14513 claims |
| BayerNubeqa | $37 | $168,07314 claims |
| Johnson & JohnsonErleada, Xarelto | $66 | $164,93423 claims |
| Rigel Pharmaceuticals, Inc.Tavalisse | $30 | $158,49811 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 1,363 hematology & oncology providers in California.
Other hematology & oncology in la Mesa
- Dennis SlamonLos Angeles$3.1M
- Sandra HorningStanford$2.5M
- Mohammadbagher ZiariCorona$2.5M
- George YaghmourLos Angeles$1.9M
- Robert VescioWest Hollywood$1.1M
- Kevin KellyLos Angeles$894K
- Johnny ChangEncino$884K
- Nitin RohatgiSacramento$814K
- Omid HamidSanta Monica$809K
- Catherine CoombsOrange$786K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.